Optimizing clinical development strategy for the rapidly evolving I-O field

IMMUNO-ONCOLOGY INSIGHTS

March 2022

Optimizing clinical development strategy for the rapidly evolving I-O field

Download PDF

Foreword

Spotlight on optimizing clinical development strategy

Spotlight on optimizing clinical development strategy

Jill O'Donnell-Tormey

Commentary

Cancer immunotherapy & clinical trial design: issues & practice

Cancer immunotherapy & clinical trial design: issues & practice

Janet E Dancey, MD, FRCPC

Beyond PD-L1: novel predictive biomarkers for adjuvant immunotherapy in renal cell and urothelial carcinoma

Beyond PD-L1: novel predictive biomarkers for adjuvant immunotherapy in renal cell and urothelial carcinoma

Jason Brown, Aarthi Rajkumar, Jorge Garcia

The cutting edge: leveraging pre-surgical immunotherapy trials to understand therapeutic mechanisms

The cutting edge: leveraging pre-surgical immunotherapy trials to understand therapeutic mechanisms

Bailey G Fitzgerald, Matthew D Galsky, Thomas U Marron

Interview

Expediting drug development & targeting early-stage disease: how is clinical trial design in immuno-oncology evolving?

Expediting drug development & targeting early-stage disease: how is clinical trial design in immuno-oncology evolving?

Immunotherapy questions in melanoma

Immunotherapy questions in melanoma

10 February 2022

Review

Expanding the reach of immuno-oncology: considerations for optimizing treatment of solid malignancies in the future

Expanding the reach of immuno-oncology: considerations for optimizing treatment of solid malignancies in the future

Luke Mantle, Samuel D Saibil

Viewpoint

Critical collaboration: Efforts to expand clinical trial eligibility

Critical collaboration: Efforts to expand clinical trial eligibility

28 February 2022